Veryan’s BioMimics 3D™ stent technology, intended to improve the biomechanical and blood flow characteristics of vascular stents.


Veryan is a specialist company in vascular disease that has developed and patented a three-dimensional stent technology, BioMimics 3D™, the aim of which is to improve upon the biomechanical and flow characteristics of straight tubular stents, particularly those used in the arteries of the leg.

Existing stents indicated for placement in the leg arteries have a straight, tubular design that tends to straighten any curvature present in vessels. This straightening effect may interfere with normal shortening of the femoropopliteal artery during lower limb movement, such as when the knee is bent. In addition, fracture of Nitinol stents has been reported in the femoropopliteal application. The inherent shortcomings of exisiting straight tubular stents are driving Veryan’s development of BioMimics 3D™ technology.

BioMimics 3D is indicated for use in the treatment of patients with peripheral arterial disease requiring endovascular intervention to relieve obstruction or occlusion of the femoropopliteal artery. The design of the BioMimics 3D stent is built on the principles underlying the latest generation of Nitinol stent technology - adequate mechanical radial support and plaque coverage, good flexibility, durability against fracture, clear visualisation and delivery accuracy - with the addition of the biomechanical and flow characteristics arising from the 3D geometry.

Veryan has acheived CE Mark approval for the BioMimics 3D stent, enabling its sale withing the European Economic Area.

During 2014, Veryan published full two-year data from its Mimics randomised controlled study of the BioMimics stent system. Results confirmed that BioMimics 3D provides a significant improvement in long term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention.

These results represent independent evaluation of Veryan's stent technology and confirm that the stent provides outstanding benefits in terms of improved blood flow and vascular compatibility.

In 2015, Veryan announced the enrollment of the first subject in its MIMICS-2 study, which will provide data to support a US Premarket Approval Application.

The research behind Veryan's technology was originally carried out by Professor Colin Caro at Imperial College London.


Veryan’s BioMimics 3D stent is initially targeted at the market for peripheral stents, which exceeds £1 billion per year with a 20% CAGR due to the emergence of new technology and expanding indications for vascular stents.

Investment History

Veryan has raised total funding to date of £18.6m in equity and loan stock, from investors Oxford Capital Partners, Seroba Kernel Life Sciences and NESTA, alongside Imperial Innovations.

In January 2015, Innovations led a £18m series B funding round alongside co-investors Invesco Asset Management, Seroba Kernel and Seven Mile.

Veryan Medical
Our investment

% share holding

Carrying value

Imperial College London

Investment stage
post-Series A

Imperial Innovation news

Key milestones

  • January 2015

    Veryan Enters Into Distribution Agreement with Biosensors International for BioMimics 3D Stent

    Read more
  • January 2015

    Innovations leads £18m series B funding round in Veryan

    Read more
  • February 2014

    Two-year follow-up data shows that Veryan's helical geometry BioMimics 3D stent provides improvement in long-term patency when compared to straight nitinol stent

    Read more
  • November 2012

    Veryan receives CE Mark for its BioMimics 3D stent

    Read more
  • July 2012

    Completed enrolment of patients for its BioMimics 3D trial

  • July 2012

    Announced the appointment of medical device industry veterans Todd M. Pope and Jeffrey B. Jump as Non-executive directors

  • June 2012

    Appointment of Nick Yeo, formerly of Light Sciences, Inc., as Chief Operating Officer.

  • October 2011

    Raised £5m in a round co-led by Innovations and Seroba Kernel Life Sciences.

Imperial Innovations key people

Nigel Pitchford Nigel Pitchford
Nigel Pitchford Chief Investment Officer View profile